Monoclonal enolase-1 blocking antibody ameliorates pulmonary inflammation and fibrosis.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis (IPF) is a chronic fatal disease with limited therapeutic options. The infiltration of monocytes and fibroblasts into the injured lungs is implicated in IPF. Enolase-1 (ENO1) is a cytosolic glycolytic enzyme which could translocate onto the cell surface and act as a plasminogen receptor to facilitate cell migration via plasmin activation. Our proprietary ENO1 antibody, HL217, was screened for its specific binding to ENO1 and significant inhibition of cell migration and plasmin activation (patent: US9382331B2).

Methods

In this study, effects of HL217 were evaluated in vivo and in vitro for treating lung fibrosis.

Results

Elevated ENO1 expression was found in fibrotic lungs in human and in bleomycin-treated mice. In the mouse mod

SUBMITTER: Huang WC 

PROVIDER: S-EPMC10647181 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature